The Cooper Companies, Inc. (COO) Free Cash Flow CAGR:55.64%(TTM)
Free cash flow CAGR uses precomputed cash-flow statement history.
Over longer horizons, The Cooper Companies, Inc.'s Free Cash Flow CAGR averages 13.71% over 3 years and 6.61% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Free cash flow CAGR measures how The Cooper Companies, Inc.'s cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
COO Free Cash Flow CAGR Chart
The Cooper Companies, Inc. (COO)
COO Quarterly Free Cash Flow Growth (YoY)
Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
COO Free Cash Flow CAGR History
| Year | Start FCF | End FCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $288.10M | $433.70M | +$145.60M | +50.54% | +50.54% |
| 2024 | $215.00M | $288.10M | +$73.10M | +34.00% | +34.00% |
| 2023 | $450.40M | $215.00M | $-235.40M | -52.26% | -52.26% |
| 2022 | $524.20M | $450.40M | $-73.80M | -14.08% | -14.08% |
| 2021 | $176.20M | $524.20M | +$348.00M | +197.50% | +197.50% |
| 2020 | $421.10M | $176.20M | $-244.90M | -58.16% | -58.16% |
| 2019 | $475.30M | $421.10M | $-54.20M | -11.40% | -11.40% |
| 2018 | $466.40M | $475.30M | +$8.90M | +1.91% | +1.91% |
| 2017 | $357.00M | $466.40M | +$109.40M | +30.65% | +30.65% |
| 2016 | $147.95M | $357.00M | +$209.05M | +141.30% | +141.30% |
| 2015 | $216.76M | $147.95M | $-68.81M | -31.75% | -31.75% |
| 2014 | $237.80M | $216.76M | $-21.04M | -8.85% | -8.85% |
| 2013 | $215.34M | $237.80M | +$22.46M | +10.43% | +10.43% |
| 2012 | $232.62M | $215.34M | $-17.27M | -7.43% | -7.43% |
| 2011 | $193.91M | $232.62M | +$38.71M | +19.96% | +19.96% |
| 2010 | $129.22M | $193.91M | +$64.68M | +50.06% | +50.06% |
| 2009 | $-28.36M | $129.22M | +$157.58M | N/A | N/A |
| 2008 | $-49.64M | $-28.36M | +$21.28M | N/A | N/A |
| 2007 | $7.85M | $-49.64M | $-57.49M | -732.21% | N/A |
| 2006 | $66.75M | $7.85M | $-58.90M | -88.24% | -88.24% |
| 2005 | $60.69M | $66.75M | +$6.06M | +9.98% | +9.98% |
| 2004 | $45.68M | $60.69M | +$15.01M | +32.85% | +32.85% |
| 2003 | $32.51M | $45.68M | +$13.17M | +40.51% | +40.51% |
| 2002 | $8.63M | $32.51M | +$23.89M | +276.83% | +276.83% |
| 2001 | $1.92M | $8.63M | +$6.71M | +349.61% | +349.61% |
| 2000 | $17.60M | $1.92M | $-15.68M | -89.10% | -89.10% |
| 1999 | $-42.50M | $17.60M | +$60.10M | N/A | N/A |
| 1998 | $3.90M | $-42.50M | $-46.40M | -1189.74% | N/A |
| 1997 | $300.00K | $3.90M | +$3.60M | +1200.00% | +1200.00% |
Quarterly Free Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | $96.40M | -39.3% | +432.6% |
| Q1 2026 | $158.70M | +5.9% | +56.8% |
| Q4 2025 | $149.90M | -8.9% | +17.0% |
| Q3 2025 | $164.50M | +808.8% | +38.8% |
| Q2 2025 | $18.10M | -82.1% | -50.9% |
| Q1 2025 | $101.20M | -21.0% | — |
| Q4 2024 | $128.10M | +8.1% | +338.7% |
| Q3 2024 | $118.50M | +221.1% | +129.7% |
| Q2 2024 | $36.90M | — | -27.1% |
| Q1 2024 | $4.60M | -84.2% | -94.5% |
| Q4 2023 | $29.20M | -43.4% | -18.4% |
| Q3 2023 | $51.60M | +2.0% | -76.3% |
| Q2 2023 | $50.60M | -39.5% | -42.8% |
| Q1 2023 | $83.60M | +133.5% | -23.2% |
| Q4 2022 | $35.80M | -83.5% | -67.3% |
| Q3 2022 | $217.30M | +145.8% | +20.6% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Albert G. White